{"id":351120,"date":"2026-11-18T09:32:00","date_gmt":"2026-11-18T04:02:00","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=351120"},"modified":"2026-11-18T09:32:00","modified_gmt":"2026-11-18T04:02:00","slug":"astrazeneca-pharma-share-price-strand-life-sciences","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-share-price-strand-life-sciences\/","title":{"rendered":"AstraZeneca Pharma Share Price Rises 2.24% After Letter of Intent With Reliance&#8217;s Strand Life Sciences"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>AstraZeneca Pharma share price Rs 6,168 on 17 Nov 2026, up 2.24%. LoI with Reliance unit Strand Life Sciences. Q2 FY27 PAT up 14.96% to Rs 62.33 cr. Down 29.76% YTD.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The AstraZeneca Pharma share price rose 2.24% to Rs 6,168 on 17 November 2026 after AstraZeneca Pharma India signed a letter of intent with Strand Life Sciences, a Reliance subsidiary, to explore healthcare collaboration in India. The company said the arrangement is not a related-party transaction. The stock remains down 29.76% in 2026 and well below its 52-week high of Rs 9,469.50, even after Q2 FY27 profit rose 14.96% to Rs 62.33 crore.<\/p>\n<\/p><\/div>\n<p>The <strong>AstraZeneca Pharma share price<\/strong> closed 2.24% higher at Rs 6,168 on 17 November 2026 after the company announced a letter of intent with Strand Life Sciences, a subsidiary of Reliance. The news gave a lift to a stock that has had a difficult year, falling close to 30% since January.<\/p>\n<p>Here is what the agreement covers, how the stock has performed, what the latest results show and the events investors should track.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=astrazeneca-pharma-share-price-strand-life-sciences\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-share-price-strand-life-sciences\/#AstraZeneca_Pharma_Share_Price_Key_Numbers\" title=\"AstraZeneca Pharma Share Price: Key Numbers\">AstraZeneca Pharma Share Price: Key Numbers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-share-price-strand-life-sciences\/#The_Letter_of_Intent_With_Strand_Life_Sciences\" title=\"The Letter of Intent With Strand Life Sciences\">The Letter of Intent With Strand Life Sciences<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-share-price-strand-life-sciences\/#Why_a_Genomics_Partnership_Could_Matter\" title=\"Why a Genomics Partnership Could Matter\">Why a Genomics Partnership Could Matter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-share-price-strand-life-sciences\/#Q2_FY27_Results_and_DCGI_Approval\" title=\"Q2 FY27 Results and DCGI Approval\">Q2 FY27 Results and DCGI Approval<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-share-price-strand-life-sciences\/#Corporate_Event_Independent_Director_E-Voting\" title=\"Corporate Event: Independent Director E-Voting\">Corporate Event: Independent Director E-Voting<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-share-price-strand-life-sciences\/#What_Investors_Should_Watch\" title=\"What Investors Should Watch\">What Investors Should Watch<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-share-price-strand-life-sciences\/#Final_Word_on_AstraZeneca_Pharma_Share_Price\" title=\"Final Word on AstraZeneca Pharma Share Price\">Final Word on AstraZeneca Pharma Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-share-price-strand-life-sciences\/#Frequently_Asked_Questions_on_AstraZeneca_Pharma_Share_Price\" title=\"Frequently Asked Questions on AstraZeneca Pharma Share Price\">Frequently Asked Questions on AstraZeneca Pharma Share Price<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-share-price-strand-life-sciences\/#Why_did_AstraZeneca_Pharma_share_price_rise_on_17_November_2026\" title=\"Why did AstraZeneca Pharma share price rise on 17 November 2026?\">Why did AstraZeneca Pharma share price rise on 17 November 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-share-price-strand-life-sciences\/#What_is_Strand_Life_Sciences\" title=\"What is Strand Life Sciences?\">What is Strand Life Sciences?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-share-price-strand-life-sciences\/#What_were_AstraZeneca_Pharma_Indias_Q2_FY27_results\" title=\"What were AstraZeneca Pharma India&#8217;s Q2 FY27 results?\">What were AstraZeneca Pharma India&#8217;s Q2 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-share-price-strand-life-sciences\/#How_has_AstraZeneca_Pharma_stock_performed_in_2026\" title=\"How has AstraZeneca Pharma stock performed in 2026?\">How has AstraZeneca Pharma stock performed in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-share-price-strand-life-sciences\/#What_is_Datverzo\" title=\"What is Datverzo?\">What is Datverzo?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/astrazeneca-pharma-share-price-strand-life-sciences\/#When_is_the_AstraZeneca_Pharma_e-voting_for_the_independent_director\" title=\"When is the AstraZeneca Pharma e-voting for the independent director?\">When is the AstraZeneca Pharma e-voting for the independent director?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"AstraZeneca_Pharma_Share_Price_Key_Numbers\"><\/span><strong>AstraZeneca Pharma Share Price: Key Numbers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Here is how the <strong>AstraZeneca Pharma share price<\/strong> has moved across time frames:<\/p>\n<table>\n<tr>\n<td><strong>Metric<\/strong><\/td>\n<td><strong>Figure<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Close on 17 Nov 2026<\/td>\n<td>Rs 6,168 (+2.24%)<\/td>\n<\/tr>\n<tr>\n<td>One week<\/td>\n<td>-5.36%<\/td>\n<\/tr>\n<tr>\n<td>One month<\/td>\n<td>+3.27%<\/td>\n<\/tr>\n<tr>\n<td>Year to date<\/td>\n<td>-29.76%<\/td>\n<\/tr>\n<tr>\n<td><strong>52-week high<\/strong><\/td>\n<td>Rs 9,469.50 (18 Nov 2025)<\/td>\n<\/tr>\n<tr>\n<td>Year low<\/td>\n<td>Rs 5,640 (9 Oct 2026)<\/td>\n<\/tr>\n<tr>\n<td>Market capitalisation<\/td>\n<td>Rs 15,398.75 crore<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"The_Letter_of_Intent_With_Strand_Life_Sciences\"><\/span><strong>The Letter of Intent With Strand Life Sciences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/univest.in\/stocks\/astrazen\/astrazeneca-pharma-india-ltd-share-price-today\">AstraZeneca Pharma India<\/a> signed a <strong>letter of intent<\/strong> on 17 November 2026 with <strong>Strand Life Sciences<\/strong>, a genomics and diagnostics company owned by <strong>Reliance<\/strong>, to explore collaboration in healthcare in India. In its exchange filing, the company said the arrangement is not a related-party transaction.<\/p>\n<p>A letter of intent is a preliminary step that sets out the intention to work together; it is not a binding contract with defined financial terms. Investors should wait for any definitive agreement to understand the scope, revenue potential and obligations involved. Until then, the AstraZeneca Pharma share price is likely to trade more on results and approvals.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Track Pharma Stocks on the Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_a_Genomics_Partnership_Could_Matter\"><\/span><strong>Why a Genomics Partnership Could Matter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Strand Life Sciences works in genomic testing and diagnostics. AstraZeneca&#8217;s portfolio in India includes a strong presence in <strong>oncology<\/strong>, where genetic testing increasingly guides which patients receive which therapies. Collaboration between a diagnostics provider and a drug company can help identify eligible patients earlier and widen access to targeted treatments.<\/p>\n<p>Chaitanya Auti, Research Analyst at Univest, notes that the AstraZeneca Pharma share price reaction was measured, which fits the preliminary nature of the announcement. The market is likely to look for a definitive agreement and early commercial details before re-rating the stock on this news.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY27_Results_and_DCGI_Approval\"><\/span><strong>Q2 FY27 Results and DCGI Approval<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Profit after tax rose 14.96% to Rs 62.33 crore in <strong>Q2 FY27<\/strong>.<\/li>\n<li>Revenue rose 30.41% to Rs 729.1 crore.<\/li>\n<li>The Drug Controller General of India granted <strong>DCGI approval<\/strong> in November 2026 for Datverzo, a breast cancer therapy, expanding the company&#8217;s oncology portfolio.<\/li>\n<\/ul>\n<p>Revenue growth of over 30% shows strong demand for the company&#8217;s products, though profit grew more slowly, suggesting higher costs during the quarter. These numbers frame the <strong>AstraZeneca Pharma share price<\/strong> more than the letter of intent does.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Corporate_Event_Independent_Director_E-Voting\"><\/span><strong>Corporate Event: Independent Director E-Voting<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Shareholders are voting on the appointment of an independent director through <strong>e-voting<\/strong>, which runs from 18 November to 17 December 2026. Investors holding the stock can vote through their depository or the e-voting platform listed in the company&#8217;s notice. The vote is a governance matter and is not expected to move the AstraZeneca Pharma share price by itself.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Investors_Should_Watch\"><\/span><strong>What Investors Should Watch<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Four triggers could move the <strong>AstraZeneca Pharma share price<\/strong> in coming months:<\/p>\n<ol>\n<li>Whether the letter of intent turns into a definitive agreement, and its terms.<\/li>\n<li>Launch timeline and uptake of Datverzo in India.<\/li>\n<li>Margin trends in coming quarters after the gap between revenue and profit growth.<\/li>\n<li>The Rs 5,640 year low as the key support, and round-number zones such as Rs 6,500 above the current price.<\/li>\n<\/ol>\n<p>Investors comparing <strong>pharma stocks<\/strong> can review sector peers such as <a href=\"https:\/\/univest.in\/stocks\/glenmark\/glenmark-pharmaceuticals-ltd-share-price-today\">Glenmark Pharmaceuticals<\/a> on growth and valuation before making decisions.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get pharma sector research and stock analysis.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Word_on_AstraZeneca_Pharma_Share_Price\"><\/span><strong>Final Word on AstraZeneca Pharma Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>AstraZeneca Pharma share price<\/strong> gained 2.24% to Rs 6,168 on 17 November 2026 after a letter of intent with Reliance&#8217;s Strand Life Sciences to explore healthcare collaboration. Q2 revenue grew over 30% and a new oncology approval adds to the pipeline, but the stock is still down nearly 30% this year. A definitive agreement and margin recovery are the next triggers to watch.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_AstraZeneca_Pharma_Share_Price\"><\/span><strong>Frequently Asked Questions on AstraZeneca Pharma Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_AstraZeneca_Pharma_share_price_rise_on_17_November_2026\"><\/span><strong>Why did AstraZeneca Pharma share price rise on 17 November 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> AstraZeneca Pharma India shares rose 2.24% to Rs 6,168 on 17 November 2026 after the company signed a letter of intent with Strand Life Sciences, a Reliance subsidiary, to explore collaboration in healthcare in India. The company said the arrangement is not a related-party transaction. A letter of intent is preliminary and does not yet include binding financial terms.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Strand_Life_Sciences\"><\/span><strong>What is Strand Life Sciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Strand Life Sciences is a genomics and diagnostics company owned by Reliance. It works in genetic testing and related healthcare services. A collaboration with AstraZeneca Pharma India could connect genetic testing with targeted therapies, particularly in areas such as oncology, where test results increasingly guide treatment decisions for patients.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_AstraZeneca_Pharma_Indias_Q2_FY27_results\"><\/span><strong>What were AstraZeneca Pharma India&#8217;s Q2 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> For the second quarter of fiscal 2027, AstraZeneca Pharma India reported profit after tax of Rs 62.33 crore, up 14.96% from a year earlier, on revenue of Rs 729.1 crore, up 30.41%. Revenue grew faster than profit, indicating higher costs during the quarter. Investors will watch whether margins improve in the coming quarters.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_AstraZeneca_Pharma_stock_performed_in_2026\"><\/span><strong>How has AstraZeneca Pharma stock performed in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> AstraZeneca Pharma India shares are down 29.76% year to date as of 17 November 2026, closing at Rs 6,168. The stock hit a 52-week high of Rs 9,469.50 on 18 November 2025 and a year low of Rs 5,640 on 9 October 2026. It gained 3.27% over the past month but fell 5.36% over the past week.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Datverzo\"><\/span><strong>What is Datverzo?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Datverzo is a breast cancer therapy for which AstraZeneca Pharma India received approval from the Drug Controller General of India in November 2026. The approval expands the company&#8217;s oncology portfolio in India. Its contribution to revenue will depend on launch timing, pricing, uptake by doctors and patients, and competition from other therapies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_is_the_AstraZeneca_Pharma_e-voting_for_the_independent_director\"><\/span><strong>When is the AstraZeneca Pharma e-voting for the independent director?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> E-voting on the appointment of an independent director at AstraZeneca Pharma India runs from 18 November to 17 December 2026. Shareholders holding the stock on the cut-off date mentioned in the notice can vote through their depository participant or the e-voting platform specified by the company in its postal ballot notice.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Why did AstraZeneca Pharma share price rise on 17 November 2026?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"AstraZeneca Pharma India shares rose 2.24% to Rs 6,168 on 17 November 2026 after the company signed a letter of intent with Strand Life Sciences, a Reliance subsidiary, to explore collaboration in healthcare in India. The company said the arrangement is not a related-party transaction. A letter of intent is preliminary and does not yet include binding financial terms.\"}},{\"@type\":\"Question\",\"name\":\"What is Strand Life Sciences?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Strand Life Sciences is a genomics and diagnostics company owned by Reliance. It works in genetic testing and related healthcare services. A collaboration with AstraZeneca Pharma India could connect genetic testing with targeted therapies, particularly in areas such as oncology, where test results increasingly guide treatment decisions for patients.\"}},{\"@type\":\"Question\",\"name\":\"What were AstraZeneca Pharma India's Q2 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"For the second quarter of fiscal 2027, AstraZeneca Pharma India reported profit after tax of Rs 62.33 crore, up 14.96% from a year earlier, on revenue of Rs 729.1 crore, up 30.41%. Revenue grew faster than profit, indicating higher costs during the quarter. Investors will watch whether margins improve in the coming quarters.\"}},{\"@type\":\"Question\",\"name\":\"How has AstraZeneca Pharma stock performed in 2026?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"AstraZeneca Pharma India shares are down 29.76% year to date as of 17 November 2026, closing at Rs 6,168. The stock hit a 52-week high of Rs 9,469.50 on 18 November 2025 and a year low of Rs 5,640 on 9 October 2026. It gained 3.27% over the past month but fell 5.36% over the past week.\"}},{\"@type\":\"Question\",\"name\":\"What is Datverzo?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Datverzo is a breast cancer therapy for which AstraZeneca Pharma India received approval from the Drug Controller General of India in November 2026. The approval expands the company's oncology portfolio in India. Its contribution to revenue will depend on launch timing, pricing, uptake by doctors and patients, and competition from other therapies.\"}},{\"@type\":\"Question\",\"name\":\"When is the AstraZeneca Pharma e-voting for the independent director?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"E-voting on the appointment of an independent director at AstraZeneca Pharma India runs from 18 November to 17 December 2026. Shareholders holding the stock on the cut-off date mentioned in the notice can vote through their depository participant or the e-voting platform specified by the company in its postal ballot notice.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca Pharma India gained after signing a letter of intent with Reliance&#8217;s Strand Life Sciences to explore healthcare collaboration. The deal, the Q2 numbers and the levels investors are watching.<\/p>\n","protected":false},"author":38,"featured_media":351118,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[25364,25363,25366,1007,610,25365],"class_list":["post-351120","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-astrazeneca-pharma-india","tag-astrazeneca-pharma-share-price","tag-datverzo","tag-pharma-stocks","tag-reliance","tag-strand-life-sciences"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["351118"],"rank_math_title":["AstraZeneca Pharma Share Price Up 2.24% on Strand LoI"],"rank_math_description":["AstraZeneca Pharma share price rose 2.24% to Rs 6,168 on 17 Nov 2026 after a letter of intent with Reliance unit Strand Life Sciences. Q2 numbers, DCGI nod and levels."],"rank_math_focus_keyword":["AstraZeneca Pharma share price"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/astrazeneca-pharma-share-price-rises-2-24-after-letter-of-intent-with-reliance-s.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/351120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=351120"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/351120\/revisions"}],"predecessor-version":[{"id":351121,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/351120\/revisions\/351121"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/351118"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=351120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=351120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=351120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}